Ankylosing Spondylitis Market to Hit $5,140.94 Million by 2030 at 4.6% CAGR - Global Analysis by Allied Market Research

The high cost of therapy and adverse effects of drugs used for treatment may hinder the growth of the market.

Ankylosing spondylitis (AS) is a type of arthritis that affects the spine and other joints. It is a chronic condition characterized by inflammation in the joints, leading to pain and stiffness. The disease is more common in men than women and often starts in early adulthood. The market for ankylosing spondylitis treatments is growing, driven by the increasing prevalence of the disease and the growing demand for effective treatments. The market is expected to reach 𝐔𝐒$ $8,110.59 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2030, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 4.6% 𝐟𝐫𝐨𝐦 2021𝐭𝐨 2030.

There are several drugs available for the treatment of ankylosing spondylitis, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), tumor necrosis factor (TNF) inhibitors, and interleukin-17 (IL-17) inhibitors. Biologic drugs, such as TNF inhibitors and IL-17 inhibitors, have been shown to be effective in treating ankylosing spondylitis, and their sales are growing rapidly.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (220 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐅𝐢𝐠𝐮𝐫𝐞𝐬):https://www.alliedmarketresearch.com/request-sample/10631

Major players operating in the ankylosing spondylitis market include 𝐀𝐛𝐛𝐕𝐢𝐞, 𝐈𝐧𝐜,,𝐀𝐦𝐠𝐞𝐧, 𝐈𝐧𝐜,,𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 𝐚𝐧𝐝 𝐂𝐨𝐦𝐩𝐚𝐧𝐲,𝐆𝐢𝐥𝐞𝐚𝐝 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬,𝐉𝐚𝐧𝐬𝐬𝐞𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬,𝐌𝐞𝐫𝐜𝐤 & 𝐂𝐨. 𝐈𝐧𝐜,𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 𝐀𝐆,,𝐏𝐟𝐢𝐳𝐞𝐫, 𝐈𝐧𝐜,𝐑𝐞𝐥𝐢𝐚𝐧𝐜𝐞 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐏𝐯𝐭. 𝐋𝐭𝐝,𝐔𝐂𝐁, 𝐈𝐧𝐜.. These companies are focused on research and development to bring new and innovative treatments to the market, and they are also involved in strategic partnerships and acquisitions to expand their market presence.

The advancement in ankylosing spondylitis therapy is one of the key drivers of the ankylosing spondylitis market growth. The development of new and effective treatments, such as monoclonal antibodies like Taltz, has helped improve the management of the disease and reduced its symptoms. This, in turn, has led to an increase in demand for these treatments, contributing to the growth of the market.

However, the high cost of ankylosing spondylitis therapy is a major challenge for the market. The cost of advanced treatments, such as biologics, can be quite high, making it difficult for patients to access these treatments. Additionally, the adverse effects associated with the drugs used for the treatment of ankylosing spondylitis also limit their usage and contribute to the market growth being restricted.

The growth of the global ankylosing spondylitis market is majorly driven by an increase in prevalence of ankylosing spondylitis. For instance, according to paper published in Scandinavian Journal of Rheumatology, in 2020, titled 'Prevalence of ankylosing spondylitis in Spain', the study found that about 7.3% population shows positive screening for ankylosing spondylitis. Furthermore, rise in number of orthopedic hospitals and diagnostic centers boost the diagnosis and treatment of diseases. For instance, according to Definitive Healthcare data in 2020 there are more than 30,500 orthopedic surgeons in the U.S.

𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐄𝐱𝐩𝐞𝐫𝐭: https://www.alliedmarketresearch.com/connect-to-analyst/10631

𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧

In North America, the ankylosing spondylitis market is further segmented into the United States and Canada. The United States has the largest market share, driven by the high prevalence of the disease and the availability of advanced treatments. Additionally, the presence of a large number of pharmaceutical companies and the high healthcare expenditure in the country also contribute to the growth of the market.

In Europe, the ankylosing spondylitis market is segmented into Western Europe and Eastern Europe. Western Europe is the largest market in Europe, with countries such as Germany, France, the United Kingdom, and Italy contributing significantly to the market. The growth in this region is driven by the high prevalence of the disease, the availability of advanced treatments, and the presence of a large number of pharmaceutical companies.

In Asia-Pacific, the ankylosing spondylitis market is segmented into Japan, China, India, and the rest of Asia-Pacific. The market in this region is growing, driven by the increasing prevalence of the disease and the growing demand for advanced treatments. In addition, the increasing healthcare expenditure and the rising awareness about the disease also contribute to the growth of the market.

The Rest of the World (RoW) includes countries in Latin America, the Middle East, and Africa. The market in this region is growing, driven by the increasing prevalence of the disease and the growing demand for advanced treatments. The market in this region is expected to grow at a significant rate in the coming years, driven by the increasing healthcare expenditure and the growing awareness about the disease.

𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐚𝐧𝐤𝐲𝐥𝐨𝐬𝐢𝐧𝐠 𝐬𝐩𝐨𝐧𝐝𝐲𝐥𝐢𝐭𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐭𝐡𝐞 𝐭𝐲𝐩𝐞 𝐨𝐟 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐝𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐜𝐡𝐚𝐧𝐧𝐞𝐥.

In terms of treatment type, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) inhibitors, and others. The TNF inhibitors segment is expected to grow at the highest rate, driven by their effectiveness in treating the disease and the growing demand for biologic treatments.

In terms of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is the largest, driven by the high demand for advanced treatments and the availability of a wide range of products in hospitals.

𝐐𝐮𝐢𝐜𝐤𝐥𝐲 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐀𝐧𝐤𝐲𝐥𝐨𝐬𝐢𝐧𝐠 𝐒𝐩𝐨𝐧𝐝𝐲𝐥𝐢𝐭𝐢𝐬
𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 : https://www.alliedmarketresearch.com/checkout-final/3f1930e0a001cc3d75d1ac8988620112

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 :

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.